CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 129 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $327,638,000 | -20.2% | 64,369 | -0.7% | 0.00% | – |
| Q2 2021 | $410,495,000 | +79.4% | 64,849 | +119.1% | 0.00% | – |
| Q1 2021 | $228,769,000 | -29.3% | 29,595 | -40.1% | 0.00% | – |
| Q4 2020 | $323,381,000 | -1.5% | 49,371 | 0.0% | 0.00% | – |
| Q3 2020 | $328,318,000 | +27.4% | 49,371 | +59.6% | 0.00% | – |
| Q2 2020 | $257,656,000 | +22.5% | 30,931 | +12.8% | 0.00% | – |
| Q1 2020 | $210,296,000 | -26.8% | 27,418 | -20.7% | 0.00% | – |
| Q4 2019 | $287,385,000 | +5.1% | 34,583 | -6.7% | 0.00% | – |
| Q3 2019 | $273,459,000 | -14.7% | 37,054 | +29.7% | 0.00% | – |
| Q2 2019 | $320,489,000 | +21.2% | 28,564 | +16.2% | 0.00% | – |
| Q1 2019 | $264,343,000 | +34.7% | 24,590 | +89.2% | 0.00% | – |
| Q4 2018 | $196,300,000 | -18.4% | 13,000 | 0.0% | 0.00% | – |
| Q3 2018 | $240,500,000 | -13.1% | 13,000 | +7.4% | 0.00% | – |
| Q2 2018 | $276,606,000 | – | 12,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,576,471 | $36,526,000 | 1.44% |
| Altium Capital Management LP | 273,703 | $1,793,000 | 0.67% |
| Jackson Creek Investment Advisors LLC | 80,367 | $526,000 | 0.21% |
| HARBOURVEST PARTNERS LLC | 79,193 | $519,000 | 0.20% |
| XTX MARKETS LLC | 14,169 | $93,000 | 0.19% |
| Perceptive Advisors | 2,577,043 | $16,880,000 | 0.18% |
| RTW INVESTMENTS, LP | 1,527,352 | $10,004,000 | 0.17% |
| Exane Asset Management | 30,568 | $200,220,000 | 0.14% |
| Virtus ETF Advisers LLC | 37,343 | $245,000 | 0.10% |
| Congress Park Capital LLC | 25,807 | $169,000 | 0.10% |